The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects
Open Access
- 21 April 2006
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 62 (3) , 336-344
- https://doi.org/10.1111/j.1365-2125.2006.02661.x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adultsAIDS, 2005
- Mechanism-Based Inactivation of CYP3A by HIV Protease InhibitorsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Pharmacokinetic Enhancement of Protease Inhibitor TherapyClinical Pharmacokinetics, 2004
- Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail”Clinical Pharmacology & Therapeutics, 2003
- Lopinavir/RitonavirDrugs, 2003
- Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell lineJournal of Pharmaceutical Sciences, 2001
- Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administrationBritish Journal of Clinical Pharmacology, 2001
- Principles and practice of HIV‐protease inhibitor pharmacoenhancementHIV Medicine, 2001
- Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir*Clinical Pharmacology & Therapeutics, 1998
- RitonavirClinical Pharmacokinetics, 1998